4-Sep-2026
Liquidia Gains FDA Fast Track for YUTREPIA in Raynaud’s
TipRanks (Thu, 3-Sep 8:51 AM ET)
Globe Newswire (Thu, 3-Sep 7:30 AM ET)
Wells Fargo Sticks to Their Buy Rating for Liquidia Technologies (LQDA)
TipRanks (Wed, 2-Sep 11:05 AM ET)
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
Globe Newswire (Wed, 2-Sep 8:30 AM ET)
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
Globe Newswire (Tue, 1-Sep 8:30 AM ET)
Liquidia Corporation Reports Second Quarter 2026 Financial Results
Globe Newswire (Wed, 12-Aug 6:30 AM ET)
Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026
Globe Newswire (Wed, 29-Jul 8:30 AM ET)
Liquidia Highlights Patient-Focused Research and Caregiver Insights at 2026 PH Conference
Market Chameleon (Fri, 12-Jun 7:43 AM ET)
Market Chameleon (Thu, 11-Jun 4:44 AM ET)
Globe Newswire (Thu, 11-Jun 8:30 AM ET)
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Liquidia trades on the NASDAQ stock market under the symbol LQDA.
As of September 4, 2026, LQDA stock price climbed to $68.66 with 815,736 million shares trading.
LQDA has a beta of 0.40, meaning it tends to be less sensitive to market movements. LQDA has a correlation of 0.01 to the broad based SPY ETF.
LQDA has a market cap of $6.10 billion. This is considered a Mid Cap stock.
Last quarter Liquidia reported $172 million in Revenue and $.74 earnings per share. This beat revenue expectation by $4 million and missed earnings estimates by -$.07.
In the last 3 years, LQDA traded as high as $93.61 and as low as $5.71.
The top ETF exchange traded funds that LQDA belongs to (by Net Assets): VTI, VXF, IJT, IWO, SPSM.
LQDA has outperformed the market in the last year with a return of +138.1%, while the SPY ETF gained +19.8%. In the last 3 month period, LQDA beat the market returning +9.8%, while SPY returned +2.0%. However, in the most recent 2 weeks LQDA has underperformed the stock market by returning +0.1%, while SPY returned +0.6%.
LQDA support price is $65.93 and resistance is $71.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LQDA shares will trade within this expected range on the day.